Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction1
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Subscribe To Our Newsletter & Stay Updated
